Vanda (VNDA): Rega marang dodolan

Vanda Pharmaceuticals (VNDA) is currently transforming its portfolio due to the loss of patent protection. The enterprise value-to-revenue multiple clearly illustrates this trend, where the 1.00 level reflects the state of the business valuation parameter. Risks are exacerbated by logistical dependence on Asia and ownership disputes. Meanwhile, management seeks to monetize existing developments in the fields of psychology and sleep.

The P/S ratio, equal to 1.00, compares the market capitalization of Vanda Pharmaceuticals (VNDA) to its annual sales volume, allowing for an assessment of the value of each unit of revenue regardless of operating expenses. By analyzing the revenue multiple dynamics, an investor identifies pricing disparities, which in this case are offset by the protection of the patent portfolio and the absence of generics, supporting stable margins within the psychoneurological drug niche.